Highlights

  • Firebrick is developing and commercialising povidone-iodine-based nasal and throat products.
  • The company reported Indonesian approval for Nasodine Nasal Spray in 2026.
  • Nasodine Throat Spray became available in Singapore during 2026.
  • A New Zealand formulation Patent extended a component of Nasodine protection to 2041.
  • Commercial rollout depends on country-specific approvals and distributor execution.

Firebrick Pharma Limited (ASX:FRE) develops and commercialises pharmaceutical formulations based on povidone-iodine, an antiseptic ingredient. Its principal product is Nasodine Nasal Spray, with follow-on products developed under the same brand. In 2026, Firebrick reported further steps in its international distribution, product range and intellectual property strategy, including a nasal spray approval in Indonesia and the introduction of a throat spray in Singapore.

Nasodine Products and Regional Availability

Nasodine Nasal Spray contains 0.5% povidone-iodine and is positioned by Firebrick Pharma (ASX:FRE) within its nasal healthcare portfolio. The Business has reported commercial availability in the United States, Singapore and Fiji, while also pursuing approvals and distribution arrangements elsewhere. Each market has distinct requirements for product registration, labelling and permitted claims; availability in one Jurisdiction does not establish approval in another.

During 2026, Firebrick announced that Indonesia had approved Nasodine Nasal Spray. The company also reported the launch of Nasodine Throat Spray in Singapore. These developments illustrate a product-range strategy rather than reliance on a single nasal formulation. Firebrick Pharma (ASX:FRE) remains dependent on local market partners to establish distribution and translate regulatory access into recurring sales.

Formulation Patent Adds Intellectual Property Coverage

On 3 June 2026, Firebrick disclosed the grant of New Zealand patent 794684 for its Nasodine formulation, titled “Improved Virucidal Formulations”. The company stated that this patent expires in June 2041 and had also been granted in Australia and South Africa. Applications were pending in several other markets at the date of that announcement; pending applications are not equivalent to granted patents.

The patent covers elements of the product formulation, separate from the company’s method-of-use patent families. For Firebrick Pharma (ASX:FRE), formulation protection has practical relevance to the way it licenses products and manages competition. A patent grant does not itself establish clinical efficacy, provide Marketing approval or guarantee revenue.

Commercial Model and Funding Considerations

Firebrick has described a commercial approach combining licensing, distribution partnerships and continued product development. Its March 2026 disclosures referred to the launch of Nasodine products in selected markets and potential additions to the range. The timing and results of further market entries remain contingent on regulatory decisions, Manufacturing arrangements and partner activity.

In a 31 March 2026 announcement, Firebrick Pharma (ASX:FRE) reported firm commitments for approximately $1.5 million through a Placement of approximately 31.9 million ordinary shares at $0.047 per share. The stated uses included business development and licensing, new product development and working capital. Such financing can support operations while increasing the number of issued shares. The announcement should not be interpreted as evidence that future operating costs are fully funded.

Execution and Regulatory Factors

Country-by-country regulation remains an important constraint on expansion. Product classifications, evidence requirements and approved health claims may differ, while manufacturing, distributor performance and market Demand influence actual sales. Firebrick Pharma (ASX:FRE) must also manage expenditure associated with launching products and maintaining its intellectual property portfolio.

Key Insights

Firebrick’s reported 2026 developments connect three aspects of its business: an expanded Nasodine product range, access to an additional Southeast Asian market and longer-dated formulation patent protection in New Zealand. These are identifiable operational steps, but their financial significance depends on subsequent commercial reporting. Regulatory permissions, product uptake and cash requirements remain separate considerations.